CAR T cells made from your own cells to treat CD5 tumors
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This early-phase trial tests a type of immune-cell therapy (CAR T cells) made using T cells with a CD5-targeting “zipper” to treat certain relapsed T-cell cancers. The goal is to see if the treatment can help shrink or clear the cancer, especially enough to move toward a stem cell transplant plan.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a relapsed T-cell cancer such as T-ALL, T-NHL (including AITL/ALCL/PTCL), or related diagnoses
- Your tumor tests positive for CD5, with more than half of the cancer cells showing CD5
- You are under 75 years old, and the first few treated patients must be adults
- You must be well enough for treatment (kidney/liver tests, oxygen level, and functional status must meet thresholds)
- You must be planned for an allogeneic stem cell transplant, and your transplant team must plan to proceed if remission happens
- You must have access to a specially matched “EBV safety” T-cell line available in case of EBV flare-ups
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment using specially engineered immune cells (CAR T cells) from a past stem cell donor to attack cancer cells in people with certain types of T-cell cancers that have returned after a stem cell transplant. The goal is to see if this treatment can lead to remission so a second stem cell transplant can be done.
This trial tests a new type of immune therapy called CAR T cells that are designed to find and attack cancer cells with a CD5 marker. It may be an option for people with T-cell leukemia or lymphoma that has not responded to standard treatments.
This trial tests a new type of immune cell therapy (called CAR-T) that targets two proteins, CD5 and CD7, on the surface of T-cell leukemia or lymphoma cells. It may be an option for people whose cancer came back or didn't respond to standard treatment.
This Phase 1 study tests a personalized form of immune therapy called CAR T cells that are designed to recognize CD19, a marker on certain B-cell cancers. It may help people with difficult-to-treat (recurrent or relapsed) B-cell lymphoma or leukemia (ALL/CLL).
This trial tests a new immune cell therapy (CAR T-cells) that targets CD5 found on certain T-cell cancers. It may be an option for people whose cancer has not responded to other treatments.
This trial tests a new treatment using your own immune cells, engineered to find and attack cancer cells that have a protein called CD5. It is for people with a type of T-cell lymphoma that has come back or not responded to other treatments.
Hear when a new T-cell Acute Lymphoblastic Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.